-5%
Elagolix, the active ingredient in Orili, is a Gonadotropin-Releasing Hormone (GnRH) receptor antagonist. It functions by competitively binding to GnRH receptors in the pituitary gland, thereby inhibiting the natural GnRH signaling pathway. This inhibition leads to a dose-dependent reduction in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, resulting in decreased blood concentrations of ovarian sex hormones, specifically estradiol and progesterone. The reduction in these hormones helps manage endometriosis-related pain by decreasing estrogen levels, which can contribute to the growth and maintenance of endometrial tissue.
